The domain
brushbiopsy.com, the exact-match name for the category.
The product, the code and the development and tech support team are offered together. Meet the development and tech support team on your introduction call. They stay with the product after the sale, ready to back your five-year roadmap.
brushbiopsy.com, the exact-match name for the category.
This product site with recreated product screens, brand, offer handling, analytics and privacy plumbing.
An open, lab-neutral rail for oral brush biopsy, with a cervical self-sample module in Year 3.
A chair-to-lab demo at /demo: order, chain of custody, reader triage, sign-off, report and recall. Sample data only.
Illustrative projections below, built only from the assumptions stated on this page.
Illustrative projections, not a forecast or guarantee. BrushBiopsy has no operating history, customers or revenue. Illustrative projections, not a forecast or guarantee. Built only from the assumptions stated here; not actual results.
| Illustrative | Y1 | Y2 | Y3 | Y4 | Y5 |
|---|---|---|---|---|---|
| Customers (year end) | 6 | 24 | 60 | 120 | 210 |
| New customers | 6 | 18 | 38 | 65 | 100 |
| Blended revenue per customer | $36k | $39k | $42k | $45k | $49k |
| Revenue | $108k | $583k | $1.8M | $4.1M | $8.1M |
| Gross margin | 60% | 67% | 73% | 77% | 80% |
| Sales and marketing | $84k | $252k | $532k | $910k | $1.4M |
| R&D, quality, regulatory, G&A | $1.0M | $1.6M | $2.3M | $3.1M | $4.0M |
| EBITDA | −$1.0M | −$1.5M | −$1.5M | −$867k | $1.1M |
Method: revenue = average customers in the year × blended revenue per customer; customers at year end = start × (1 − 8% churn) + new customers; operating costs = new customers × acquisition cost + the stated fixed budget.
Illustrative product demo only. BrushBiopsy as shown here is not a medical device, is not cleared or approved by any regulator, and does not diagnose, screen for or rule out any disease. All screens use fictional sample data. Clinical decisions must be made by qualified professionals using validated, regulated tests.
the full package - product, code, and the team to take it forward
BrushBiopsy is an open, lab-neutral rail for oral brush biopsy. A dentist orders a kit, takes a painless brush sample from a white or red patch, and the platform tracks that sample from the chair, through the courier and into a partner cytology laboratory, where a qualified reader works from a prioritised triage queue. The structured report goes back to the practice and every atypical result is held on a recall register until it is closed with a referral or a histology result. Today the category is dominated by a single closed laboratory; BrushBiopsy lets any accredited lab offer the test and gives practices the tracking and follow-up they lack.
Meet the development and tech support team on your introduction call. They stay with the product after the sale, ready to back your five-year roadmap.
The development and tech support team that built the product will be introduced on the introduction call. They remain available after completion and can fully support delivery of the five-year roadmap.
This product site is built on Next.js with a working chair-to-lab demo on sample data, ready to deploy on the exact-match .com.
Brush biopsy has a dental billing code, a rising disease burden and growing AI cytology research, yet most practices still post a sample to one closed laboratory and track the result on paper. BrushBiopsy is the workflow layer: orders, chain of custody, a reader triage queue, structured reports and a recall register.
Oral cancer is rising: 389,846 new lip and oral cavity cancers worldwide in 2022 (GLOBOCAN), about 60,480 US oral cavity and pharynx cancers expected in 2026 (American Cancer Society) and a record 10,825 UK mouth cancer diagnoses a year (Oral Health Foundation). Dentists see the lesions first.
The roadmap keeps qualified readers in charge: workflow and tracking first, AI-assisted cell prioritisation through proper submissions, and a recall register that also produces the outcome evidence payers say the category lacks.
| Metric | Y1 | Y2 | Y3 | Y4 | Y5 |
|---|---|---|---|---|---|
| Customers | 6 | 24 | 60 | 120 | 210 |
| Revenue | $108k | $583k | $1.8M | $4.1M | $8.1M |
| Gross margin | 60% | 67% | 73% | 77% | 80% |
| Opex | $1.1M | $1.9M | $2.8M | $4.0M | $5.4M |
| EBITDA | −$1.0M | −$1.5M | −$1.5M | −$867k | $1.1M |
Assumptions
Meet the development and tech support team on your introduction call. They stay with the product after the sale, ready to back your five-year roadmap.
Contact: hello@brushbiopsy.com